<DOC>
	<DOCNO>NCT01576380</DOCNO>
	<brief_summary>This prospective , open-label , single-arm , non-randomized , multi-center , phase II proof concept ( PoC ) study two-stage design Bayesian interim monitoring evaluate efficacy safety single agent TKI258 adult patient scirrhous gastric carcinoma ( SGC ) progress one two prior systemic treatment .</brief_summary>
	<brief_title>A Phase II Study Evaluate Efficacy Safety Dovitinib ( TKI258 ) Advanced Scirrhous Gastric Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Stomach Diseases</mesh_term>
	<mesh_term>Adenocarcinoma , Scirrhous</mesh_term>
	<mesh_term>Linitis Plastica</mesh_term>
	<criteria>Diagnosis advanced/metastatic scirrhous gastric carcinoma Evidence diffusely infiltrate gastric lesion and/or least one measurable extragastric lesion Patients previously treat one two systemic line Documented radiological confirmation disease progression ECOG performance status 0 2 Male female patient age 20 year great Adequate liver , renal , hematologic function Patients receive prior treatment FGFR inhibitor Patients know brain metastasis signs/symptoms attributable brain metastasis assess radiologic imaging rule presence brain metastases Patients another primary malignancy within 3 year prior start study treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Advanced scirrhous gastric carcinoma</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Second-line third-line treatment</keyword>
	<keyword>VEGF</keyword>
	<keyword>FGFR</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Gastric Neoplasms</keyword>
	<keyword>Cancer</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Gastric Diseases</keyword>
	<keyword>Female Genital Diseases</keyword>
	<keyword>Tumors</keyword>
	<keyword>Oral Administration</keyword>
	<keyword>Capsules</keyword>
	<keyword>TKI258</keyword>
	<keyword>TKI-258</keyword>
	<keyword>TKI 258</keyword>
</DOC>